It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Source: www.statnews.com



